Longitudinal analysis of antibody decay in convalescent COVID-19 patients

Abstract Determining the sustainability of antibodies targeting severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is essential for predicting immune response against the Coronavirus disease 2019 (COVID-19). To quantify the antibody decay rates among the varying levels of anti-nucleocapsid...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Weiming Xia, Mingfei Li, Ying Wang, Lewis E. Kazis, Kim Berlo, Noureddine Melikechi, Gregory R. Chiklis
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/f32bbc5fac4d4f68be1005417f9bcec9
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:f32bbc5fac4d4f68be1005417f9bcec9
record_format	dspace
spelling	oai:doaj.org-article:f32bbc5fac4d4f68be1005417f9bcec92021-12-02T16:45:40ZLongitudinal analysis of antibody decay in convalescent COVID-19 patients10.1038/s41598-021-96171-42045-2322https://doaj.org/article/f32bbc5fac4d4f68be1005417f9bcec92021-08-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-96171-4https://doaj.org/toc/2045-2322Abstract Determining the sustainability of antibodies targeting severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is essential for predicting immune response against the Coronavirus disease 2019 (COVID-19). To quantify the antibody decay rates among the varying levels of anti-nucleocapsid (anti-N) Immunoglobulin G (IgG) in convalescent COVID-19 patients and estimate the length of time they maintained SARS-CoV-2 specific antibodies, we have collected longitudinal blood samples from 943 patients over the course of seven months after their initial detection of SARS-CoV-2 virus by RT-PCR. Anti-N IgG levels were then quantified in these blood samples. The primary study outcome was the comparison of antibody decay rates from convalescent patients with high or low initial levels of antibodies using a mixed linear model. Additional measures include the length of time that patients maintain sustainable levels of anti-N IgG. Antibody quantification of blood samples donated by the same subject multiple times shows a gradual decrease of IgG levels to the cutoff index level of 1.4 signal/cut-off (S/C) on the Abbott Architect SARS-CoV-2 IgG test. In addition, this study shows that antibody reduction rate is dependent on initial IgG levels, and patients with initial IgG levels above 3 S/C show a significant 1.68-fold faster reduction rate compared to those with initial IgG levels below 3 S/C. For a majority of the donors naturally occurring anti-N antibodies were detected above the threshold for only four months after infection with SARS-CoV-2. This study is clinically important for the prediction of immune response capacity in COVID-19 patients.Weiming XiaMingfei LiYing WangLewis E. KazisKim BerloNoureddine MelikechiGregory R. ChiklisNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-9 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Weiming Xia Mingfei Li Ying Wang Lewis E. Kazis Kim Berlo Noureddine Melikechi Gregory R. Chiklis Longitudinal analysis of antibody decay in convalescent COVID-19 patients
description	Abstract Determining the sustainability of antibodies targeting severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is essential for predicting immune response against the Coronavirus disease 2019 (COVID-19). To quantify the antibody decay rates among the varying levels of anti-nucleocapsid (anti-N) Immunoglobulin G (IgG) in convalescent COVID-19 patients and estimate the length of time they maintained SARS-CoV-2 specific antibodies, we have collected longitudinal blood samples from 943 patients over the course of seven months after their initial detection of SARS-CoV-2 virus by RT-PCR. Anti-N IgG levels were then quantified in these blood samples. The primary study outcome was the comparison of antibody decay rates from convalescent patients with high or low initial levels of antibodies using a mixed linear model. Additional measures include the length of time that patients maintain sustainable levels of anti-N IgG. Antibody quantification of blood samples donated by the same subject multiple times shows a gradual decrease of IgG levels to the cutoff index level of 1.4 signal/cut-off (S/C) on the Abbott Architect SARS-CoV-2 IgG test. In addition, this study shows that antibody reduction rate is dependent on initial IgG levels, and patients with initial IgG levels above 3 S/C show a significant 1.68-fold faster reduction rate compared to those with initial IgG levels below 3 S/C. For a majority of the donors naturally occurring anti-N antibodies were detected above the threshold for only four months after infection with SARS-CoV-2. This study is clinically important for the prediction of immune response capacity in COVID-19 patients.
format	article
author	Weiming Xia Mingfei Li Ying Wang Lewis E. Kazis Kim Berlo Noureddine Melikechi Gregory R. Chiklis
author_facet	Weiming Xia Mingfei Li Ying Wang Lewis E. Kazis Kim Berlo Noureddine Melikechi Gregory R. Chiklis
author_sort	Weiming Xia
title	Longitudinal analysis of antibody decay in convalescent COVID-19 patients
title_short	Longitudinal analysis of antibody decay in convalescent COVID-19 patients
title_full	Longitudinal analysis of antibody decay in convalescent COVID-19 patients
title_fullStr	Longitudinal analysis of antibody decay in convalescent COVID-19 patients
title_full_unstemmed	Longitudinal analysis of antibody decay in convalescent COVID-19 patients
title_sort	longitudinal analysis of antibody decay in convalescent covid-19 patients
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/f32bbc5fac4d4f68be1005417f9bcec9
work_keys_str_mv	AT weimingxia longitudinalanalysisofantibodydecayinconvalescentcovid19patients AT mingfeili longitudinalanalysisofantibodydecayinconvalescentcovid19patients AT yingwang longitudinalanalysisofantibodydecayinconvalescentcovid19patients AT lewisekazis longitudinalanalysisofantibodydecayinconvalescentcovid19patients AT kimberlo longitudinalanalysisofantibodydecayinconvalescentcovid19patients AT noureddinemelikechi longitudinalanalysisofantibodydecayinconvalescentcovid19patients AT gregoryrchiklis longitudinalanalysisofantibodydecayinconvalescentcovid19patients
_version_	1718383490621243392

Longitudinal analysis of antibody decay in convalescent COVID-19 patients

Ejemplares similares